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Abstract The reversible denaturation of the multifunctional 
polypeptide, cyclosporin synthetase, by urea was analyzed. It is 
possible to discriminate between at least two stages of enzyme 
denaturation. While at low urea concentration (up to 0.8 M) 
cyclosporin A formation is inhibited, synthesis of the 
diketopiperazine cyclo-(D-alanyl-N-methylleucyi), a molecule 
representing a partial sequence of cyclosporin A is still detectable. 
At higher concentrations of urea the enzyme preparation is totally 
inactive. This inactivation is a consequence of conformational 
change(s) of cyclosporin synthetase as shown by fluorescence 
emission spectra of native and denatured enzyme. These data 
imply a consecutive folding/defoiding mechanism for the different 
domains forming the multifunctional polypeptide. 
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1. Introduction 
Cyclosporin A (CyA), a powerful drug in human transplan- 
tation surgery and the treatment of autoimmune diseases [1~], 
is a cyclic undecapeptide produced by the fungus Beauveria 
nivea. 
It is synthesized by cyclosporin synthetase, a multienzyme 
polypeptide. Its molecular mass has been estimated to be about 
1,400 kDa [5] by SDS-PAGE and CsC1 density gradient centrif- 
ugation. Sequencing of the open reading frame of the cy- 
closporin synthetase gene resulted in a derived molecular mass 
of 1,689,243 Da [6]. This multifunctional polypeptide catalyzes 
CyA formation in at least 40 reaction steps in an assembly 
belt-like mechanism [7]. The enzyme activates all constituent 
amino acids of CyA as thioesters via aminoacyladenylates [7] 
and carries out specific N-methylation reactions [8]. 
Studies on chaperone functions have shown that these pro- 
teins, assisting in the folding of proteins, form complexes with 
cavities giving space for globular proteins of about 90 kDa 
[9,10]. A majority of proteins has molecular masses of about 
*Corresponding author. Monash University, Department of 
Biochemistry and Molecular Biology, Clayton, 
Victoria 3168, Australia. Fax: (61) (3) 9905-4699. 
E-mail: alfons.lawen@med.monash.edu.au 
**Present address." Institut ftir Physiologische Chemie, Tier/irztliche 
Hochschule Hannover, Biinteweg 17, D-30559 Hannover, Germany. 
***The first two authors have contributed equally to this paper. 
Abbreviations." Abu, k-2-aminobutyric acid; AdoMet, S-adenosyl-L- 
methionine; [~4C]AdoMet, S-adenosyl-L-[methyl-~4C]methionine; Bmt, 
(4R)-4-[(E)-2-butenyl]-4-methyl-k-threonine; CyA, cyclosporin A; 
cyclo-(D-Ala-MeLeu), eyclo-(D-alanyl-N-methylleucyl); Me,N-methyl-. 
this size and below. Cyclosporin synthetase is so far the largest 
known polypeptide xerting enzymatic activities. To function 
adequately it has to be folded in a very specific manner which 
cannot be assisted by the chaperone/chaperonine machineries 
in the cell as such. The sequencing of the open reading frame 
reported in [6] has demonstrated that the enzyme is composed 
of eleven major domains of about 140 kDa each. One obvious 
possibility for the folding mechanism of such a multidomain 
enzyme would be that each domain is folded by its own, assisted 
by a chaperone/chaperonine machinery. The final arrangement 
of the folded domains in relation to each other can then be 
either a spontaneous step or it could be catalyzed by specific 
enzymes (like the peptidyl-prolyl-cis/trans-isomerases [11]). 
To prove whether there would be a step-by-step defolding 
mechanism detectable for cyclosporin synthetase we analyzed 
the reaction products of this enzyme at different low urea con- 
centrations. We could show that there exist conditions under 
which some reactions are no longer catalyzed, whereas others 
(early steps of cyclosporin synthesis) are still carried out by the 
enzyme. 
2. Materials and methods 
2.1. Radioisotopes 
Radioactive [~C]D-alanine (specific activity 40 Ci/mol), [14C]L-alanine 
(155 Ci/mol), [~4C]k-leucine (308 Ci/mol), [~4C]L-valine (270 CYmol), 
[~4C]k-threonine (228 Ci/mol), [~4C]glycine (107 Ci/mol) and S-adenosyl- 
L-[methyl-~aC]methionine ([~4C]AdoMet, 59 Ci/mol) were purchased 
from Amersham Buchler (Braunschweig, Germany). [~4C]D/k-aminobu- 
tyric acid ([~4C]-Abu, 16 Ci/mol) was from DuPont NEN (Bad Hom- 
burg, Germany). ATP was from Boehringer (Mannheim, Germany). 
Bmt ((4R)-4-[(E)-2-butenyl]-4-methyl-L-threonine) a d CyA were do- 
nated by Dr. R. Traber, Sandoz Ltd. (Basel, Switzerland). 
2.2. Growth of organism, enzyme preparation, enzyme assays and thin 
layer chromatography 
These were carried out as described elsewhere [8,12]. 
2.3. In vitro o,closporin A formation in the presence of urea 
100 ,ul of enzyme preparation (pooled active HW 55 fractions) were 
preincubated in the presence of different concentrations of urea (calcu- 
lated for the final volume of 170/zl) dissolved in buffer B (0.1 M 
Tris-HCl, pH 7.8; 4 mM EDTA; 4 mM DTE; 15% (w/v) glycerol) in 
a total volume 145/11 for 10 min. Cyclosporin A synthesis reaction was 
initiated by the addition of 25 ,ul reaction mixture containing (final 
concentration i 170/zl) 6 mM MgC12, 2.5 mM ATE 0.25 ,uCi of 
[~C]AdoMet, a mixture of 0.5 mM of each of Leu, D-Ala, Val, Abu, 
Gly and Ala, 0.12 mM Bmt [12]. The reactions were carried out for 10 
min at 25°C. Further treatment was done as described elsewhere [12]. 
2.4. Determination of thioester-bound amino acids 
90,ul of cyclosporin synthetase were incubated together with 25 mM 
MgCI2, 22 mM ATE each of the constituent amino acids of CyA in 
14C-radiolabeled form (0.6/.tCi (15 nM); Bmt: 0.3 pCi [14C]AdoMet (15 
nM) and 15 nM Bmt; [14C]-D/L-Abu: 0.24 pCi (15 nM)) and urea dis- 
solved in buffer B in different concentrations in a total volume of 204 
pl. After incubation for 10 min at 25°C reaction was stopped by adding 
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1 ml of 7% trichloroacetic acid. Further sample treatment was done 
according to [13]. 
3. Results 
3.1. Reversible denaturation of cyclosporin synthetase 
The overall reaction of CyA synthesis can be divided in at 
least 40 partial reaction steps: 11 aminoacyladenylation reac- 
tions, 11 transthiolation reactions, 7 N-methylation reactions, 
10 elongation reactions and a final cyclization reaction. All 
steps are catalyzed by cyclosporin synthetase, a single polypcp- 
tide chain [7,8] consisting of eleven amino acid activating 
domains [6]. 
To investigate whether specific reaction steps of CyA forma- 
tion could be abolished by low urea concentrations, we preincu- 
bated the enzyme with various concentrations of urea. Once an 
equilibrium state of unfolding has been reached (after approx- 
imately 10 min, see below) the cyclosporin A synthesis reaction 
was started by addition of the reaction's substrates (ATP, 
Mg 2÷, [~4C]AdoMet, and a mixture of all amino acids constitu- 
tive of CyA). After stopping the reaction the overall incorpora- 
tion of radiolabelled methyl-groups (derived from [~4C]AdoMet 
in our incubation mixture) into the synthesized peptides ex- 
tractable with EtOAc was determined. Under these conditions, 
at concentrations of urea up to 2 M we found that the enzyme 
activity was exponentially decreased epending on urea con- 
centration (Fig. 1). In the presence of 0.4 M urea the catalytic 
activity of cyclosporin synthetase was already approximativcly 
50% (52.3 + 1.8%) that of the original activity. The time course 
(Fig. 1; insert) shows that urea at a concentration of 0.4 M 
needs some time (at least 5 min) to develop its full inhibitory 
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Fig. I. Denaturation of cyclosporin synthetase by urea. 100/11 of en- 
zyme preparation were preincubated together with the indicated urea 
concentrations for 10 min. The cyclosporin A synthesis reaction was 
initiated by the addition of the necessary co-factors and substrate 
amino acids and was carried out for 10 min at 25°C. Samples were 
worked up as described in section 2. 100% was set as 3,044 counts/ 
minute. Insert: Time course of enzyme activity in the presence of 0.4 
M urea. Cyclosporin synthetase was incubated together without (A) and 
with 0.4 M urea (m) and the necessary cofactors and substrate amino 
acids at 25°C. At indicated times aliquots were removed and lhe 
EtOAc-extractable radioactivity was measured. 100% was set as 7,428 
counts/minute. 
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Fig. 2. Comparison of overall catalytic activity and t3,clo-(D-Ala- 
MeLeu) formation. Enzyme preparations were incubated for 10 rain at 
25°C in the presence of urea with different substrate mixtures. As 
radiolabel [~4C]AdoMet was used. For determination of the overall 
catalytic activity (m) a mixture of all constituent amino acids of CyA, 
ATP and MgCI 2 was used. For diketopiperazine synthesis (A) only 
D-Ala and Leu (0.6 mM of each amino acid) and the necessary cofactors 
were used. 100% in overall catalytic activity represents 3,896 counts/ 
minute. In the case of diketopiperazine formation 100% was set as 984 
counts/minute. 
effect on enzyme activity reflecting the kinetic rate of unfolding 
of cyclosporin synthetase. 
When we analyzed the reaction products of these incubations 
by thin layer chromatography we could not detect any CyA 
formation at urea concentration higher than 0.8 M whereas the 
enzyme was still able to synthesize the diketopiperazine cyclo(D- 
alanyl-N-methylleucyl) (cyclo-(D-Ala-MeLeu)) (not shown). 
This molecule represents the first two amino acids of the grow- 
ing peptide chain of CyA and therefore needs only the first two 
domains of the enzyme for its formation [7,13]. 
The formation of cyclo-(D-Ala-MeLeu) could also be 
achieved when the incubation mixture containing all constitu- 
ent amino acids of CyA was replaced by a mixture containing 
only b-Ala and Leu as substrate amino acids. We have com- 
pared the overall catalytic activity of cyclosporin synthetase 
(using an incubation mixture containing all constituent amino 
acids of CyA) with the synthesis of cyclo-(D-Ala-MeLeu) (using 
as substrates D-Ala and Leu) catalyzed by the enzyme in the 
presence of urea. Whereas the dependence of cyclo-(D-Ala- 
MeLeu) formation from the urea concentration is almost lin- 
ear, the EtOAc-extractable radioactivity shows a biphasic de- 
pendence on urea concentration when the incubation mixture 
is designed for CyA biosynthesis (Fig. 2). As our TLC analyses 
show there is no CyA, but only cTclo-(l)-Ala-MeLeu) synthesis 
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Fig. 3. Reversible denaturation ofcyclosporin synthetase. The catalytic 
activity of the preparation in the absence of urea was set as 100% 
corresponding to 3,947 cpm. Enzyme preparation was preincubated 
with 0.4 M urea at 0°C for various times. At the indicated times aliquots 
were removed, diluted four times with buffer containing 0.4 M urea and 
tested for CyA activity (m) or diluted four times with an urea free buffer 
(A), resulting in a final urea concentration of 0.1 M, and kept at 0°C 
for further 30 rain. Thereafter the CyA formation activity was measured 
as described in section 2.3. 
at urea concentrations of about 0,8 M and above. So it is 
obvious that under these conditions the first phase reflects CyA 
synthesis, whereas the second phase reflects cyclo-(D-Ala- 
MeLeu) synthesis. These results suggest hat the first two do- 
mains of the enzyme which are responsible for the synthesis of 
cyclo-(D-Ala-MeLeu) are unfolded at higher urea concentration 
than some of the other nine domains. In the presence of low 
urea concentrations cyclosporin synthetase changes its catalytic 
activity leading to an enzyme which has a similar behaviour as 
the cyclosporin synthetase isolated from blocked mutant of 
Beauveria nivea, namely strain YP 582. This mutant enzyme 
does not catalyze the synthesis of CyA but the formation of the 
cyclic dipeptide [13]. 
To analyze the reversibility of the defolding of cyclosporin 
synthetase we preincubated the enzyme in the presence of 0.4 
M urea at 0°C. After dilution of urea concentration to 0.1 M 
we allowed the enzyme to refold for 30 min at 0°C and deter- 
mined thereafter the catalytic activity of the enzyme. Under 
these conditions we observed a fully reversible process of de- 
naturation (Fig. 3). 
To prove that conformational changes of the polypeptide 
chain of cyclosporin synthetase are responsible for the loss of 
catalytic activity in the presence of urea, we recorded fluores- 
cence emission spectra of the enzyme in the presence of differ- 
ent urea concentrations. The native enzyme, purified by glyc- 
erol gradient ultracentrifugation, when excited at 280 nm 
showed an emission maximum at 337.2 nm (Fig. 4). It shifted 
gradually to 341.0 nm at an urea concentration of 4 M (Fig. 4). 
A similar shift of the emission maximum was obtained when 
we analyzed the enzyme in the presence of 6 M urea (data not 
shown). In no case catalytic activity of cyclosporin synthetase 
could be detected (Fig. l). 
3.2. Formation of enzyme substrate complexes in the presence 
of  blrea 
During CyA biosynthesis substrate amino acids are activated 
in a two step mechanism. In the first step all substrate amino 
acids are activated as aminoacyladenylates. In the second step, 
these activated amino acids bind to specific active centers on 
the enzyme as thioesters under AMP liberation [7,8]. Cloning 
of the corresponding coding region of the cyclosporin synthe- 
tase gene has shown that it contains eleven amino acid activat- 
ing domains [6]. Our results obtained by fluorescence emission 
analysis have demonstrated that the polypeptide chain of the 
enzyme underwent conformational changes in the presence of 
urea. These experiments do not give informations about which 
and how many of the eleven amino acid activating domains of 
cyclosporin synthetase are denaturated by a specific urea con- 
centration. 
To differentiate between ative (active) and denatured (inac- 
tive) domains we analyzed the formation of enzyme substrate 
complexes in the presence of urea. We incubated cyclosporin 
synthetase with one of the substrate amino acids of CyA each 
in radiolabelled form, the necessary cofactors and urea in con- 
centrations up to 1.0 M. (Covalent binding of Bmt to the en- 
zyme was measured indirectly by formation of ['4C]MeBmt 
using [~4C]AdoMet and unlabelled Bmt.) In all cases examined, 
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Fig. 4. Fluorescence emission spectra of native and denaturated cy- 
closporin synthetase. Spectra of native enzyme (solid line), purified by 
glycerol gradient ultracentrifugation [8] and enzyme denaturated by 0.8 
M urea (dashed and dotted line), 2.0 M urea (dotted line) and 4.0 M 
urea (dashed line) (dissolved in 100 mM Tris-HCl pH 7.8, 4 mM ETDA, 
37.5% (w/v) glycerol and 50 mM KCI) were measured with a fluores- 
cence spectrophotometer Hitachi F4000. Excitation wavelength was 
280 nm. The insert shows the wavelength ofthe maxima plotted against 
the urea concentrations. 
160 J. Dittmann et al./FEBS Letters 380 (19963 157 160 
100 
80 
A 
o~ 60 
._z- 
< 
40 
20 
m 
0.0 0.2 0.4 0.6 0.8 1.0 
Urea (M) 
Fig. 5. Formation of enzyme substrate complexes in the presence of 
urea. Enzyme preparations were incubated with one of the substrate 
amino acids of CyA in radiolabeled form (in the case of Brat: 
[~4C]AdoMet and unlabeled Bmt were used) and urea at 25°C for 10 
rain. The reaction was stopped by adding 7% trichloroacetic a id and 
the filter bound radioactivity was measured in a scintillation counter. 
For o-Ala (D) 100% represents 80.3 pmol, for Leu (+) 131.2 pmol, for 
Val (a) 108.7 pmol, for MeBmt (*) 74.6 pmol, for o/L-Abu (o) 325.9 
pmol, for Gly (*) 41.0 pmol and for Ala (v) 40.1 pmol. For detection 
of the overall catalytic activity of cyclosporin synthetase (m) it was 
incubated together with all constituent amino acids of CyA and the 
necessary cofactors at 25°C for 10 rain. After stopping the reaction the 
EtOAc extractable radioactivity was measured. 100% were set as 3,804 
counts/minute. 
the amount of enzyme bound substrate amino acid decreased 
depending on the concentration of urea, whereby each sub- 
strate amino acid showed an individual inhibition pattern (Fig. 
5), suggesting that each of the eleven amino acid activating 
domains of the enzyme can be individually denaturated by 
specific urea concentrations. So, for example while at an urea 
concentration of 1 M the formation of the enzyme glycine 
complex is reduced below 20% of the original activity the for- 
mation of the enzyme D-Ala complex still is above 40% of the 
original activity. 
When we analyzed the biosynthetic activity of cyclosporin 
synthetase we observed that inhibition of CyA formation was 
inhibited by lower urea concentration than the thioester-bind- 
ing of substrate amino acids to the enzyme. As can be seen 
further from Fig. 5, D-AIa and Leu-thioester formation is inhib- 
ited by 1 M urea to only 50% or less, such, cyclo-(l~-Ala-MeLeu) 
formation is still possible under conditions where CyA forma- 
tion is totally inhibited. 
4. Discussion 
Biosynthesis of the cyclic undecapeptide CyA is catalyzed by 
cyclosporin synthetase a single multienzyme polypeptide [8] 
existing of eleven amino acid activating domains, seven of 
which habour N-methyltransferase activities [6]. In the presence 
of increasing amounts of urea we found a reduction of the 
catalytic activity of this enzyme. Responsible for this is (are) 
conformational change(s) of the polypeptide chain of cy- 
closporin synthetase which could be demonstrated by fluores- 
cence emission analysis. At low concentrations of urea (less 
than about 0.8 M) the CyA formation activity decreases with 
increasing urea concentrations, at medium (about 0.8 M) urea 
concentrations only a minor product is formed which was iden- 
tified to be cyclo-(D-Ala-MeLeu) while the enzyme does no 
longer synthesize CyA. The cyclic dipeptide represents the first 
two amino acids (D-Ala in position 8 and MeLeu in position 
9) of the growing peptide chain of CyA [7,13]. Formation of 
~3,c/o-(D-Ala-MeLeu) shows that medium urea concentrations 
are able to unfold some of the other nine domains of the enzyme 
whereas the two amino acid activating domains 8 and 9 are still 
functional. As shown by our studies on the formation of spe- 
cific enzyme substrate complexes each amino acid activating 
domain of cyclosporin synthetase is unfolded by urea with 
specific kinetics suggesting a defolding of rather the single do- 
mains than the whole enzyme. 
Such cyclosporin synthetase could possibly be developed to 
a model system for studying the folding/defolding mechanism 
of multi domain enzymes and of the function of chaperone/ 
chaperonine machineries and/or specific accessory enzymes like 
peptidyl-prolyl-cis/trans-isomerases in this process. 
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